Trial · NCT00726232
Participant flow80
How many started, completed or left each group, period by period.
1 to 20 of 80
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Initial Phase (Dose-finding) | STARTED | Polycythemia Vera (PV): Ruxolitinib 10 mg BID | 19 | |
| Initial Phase (Dose-finding) | STARTED | PV: Ruxolitinib 25 mg BID | 8 | |
| Initial Phase (Dose-finding) | STARTED | PV: Ruxolitinib 50 mg QD | 7 | |
| Initial Phase (Dose-finding) | STARTED | Essential Thrombocythemia (ET): Ruxolitinib 10 mg BID | 8 | |
| Initial Phase (Dose-finding) | STARTED | ET: Ruxolitinib 25 mg BID | 22 | |
| Initial Phase (Dose-finding) | STARTED | ET: Ruxolitinib 50 mg QD | 9 | |
| Initial Phase (Dose-finding) | STARTED | PV: Ruxolitinib All Doses Combined- Expansion Phase | 0 | |
| Initial Phase (Dose-finding) | STARTED | ET: Ruxolitinib All Doses Combined-expansion Phase | 0 | |
| Initial Phase (Dose-finding) | Safety Evaluable Participants | Polycythemia Vera (PV): Ruxolitinib 10 mg BID | 19 | |
| Initial Phase (Dose-finding) | Safety Evaluable Participants | PV: Ruxolitinib 25 mg BID | 8 | |
| Initial Phase (Dose-finding) | Safety Evaluable Participants | PV: Ruxolitinib 50 mg QD | 7 | |
| Initial Phase (Dose-finding) | Safety Evaluable Participants | Essential Thrombocythemia (ET): Ruxolitinib 10 mg BID | 8 | |
| Initial Phase (Dose-finding) | Safety Evaluable Participants | ET: Ruxolitinib 25 mg BID | 22 | |
| Initial Phase (Dose-finding) | Safety Evaluable Participants | ET: Ruxolitinib 50 mg QD | 9 | |
| Initial Phase (Dose-finding) | Safety Evaluable Participants | PV: Ruxolitinib All Doses Combined- Expansion Phase | 0 | |
| Initial Phase (Dose-finding) | Safety Evaluable Participants | ET: Ruxolitinib All Doses Combined-expansion Phase | 0 | |
| Initial Phase (Dose-finding) | ITT Participants | Polycythemia Vera (PV): Ruxolitinib 10 mg BID | 19 | |
| Initial Phase (Dose-finding) | ITT Participants | PV: Ruxolitinib 25 mg BID | 8 | |
| Initial Phase (Dose-finding) | ITT Participants | PV: Ruxolitinib 50 mg QD | 7 | |
| Initial Phase (Dose-finding) | ITT Participants | Essential Thrombocythemia (ET): Ruxolitinib 10 mg BID | 8 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00726232/flow